X

Trial Profile

Proof of concept study of MN-166

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 20 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibudilast (Primary)
Indications Acute lung injury; Adult respiratory distress syndrome
Focus Proof of concept; Therapeutic Use

Most Recent Events

20 May 2021 New trial record
13 May 2021 According to MediciNova media release, BRADA will provide funding for this study.
13 May 2021 According to MediciNova media release, the company has entered into a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to develop MN-166 as a potential treatment for chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com